Ce Cert.

CERTIFICATE

DIRECTIVE 98/79/EC EC DESIGN-EXAMINATION

CeCert Sp. z o.o. hereby confirms that manufactured by

Suny (Xiamen) Biotechnology Co., Ltd.

Floor 3 to 8, Building 24, No. 71 Houxiang Road, Haicang District, 361026 Xiamen, Fujian, P.R. China

in vitro diagnostic medical device for self-testing

The list of devices covered by the scope of this Certificate is included in Annex 1

in term of the design conforms to the requirements of Annex III section 6 to Directive 98/79/EC (as amended) implemented into Polish Law, as evidenced by the assessment conducted by CeCert Sp. z o.o.

 ϵ

293

Validity date: 06.05.2022 – 26.05.2025

Edition issue date: 25.05.2022

Check it

CeCert Sp. z o.o. ul. Żurawia 32/34 00-515 Warszawa Kamil Szczurowski Director of *in Vitro* Diagnostic Medical Device Certification Department

www.cecert.pl e-mail: <u>biuro@cecert.pl</u>

Certificate no: CeCert/073/W/E.2



ANNEX 1

TO THE CERTIFICATE No. CECERT/073/W/E.2

List of *in vitro* diagnostic medical devices covered by the scope of the Certificate No. CeCert/073/W/E.2:

5. 1 55. 1 55.51. 75.75, 1 1		
Brand/Trademark	Catalogue Number	Device Name
SunyBio	S6061701	
	S6061702	Rapid SARS-CoV-2&Flu A&Flu B Antigen Test
	S6061703	(Colloidal Gold) / Nasal Swab
	S6061704	
SAYEE BIOONE	B6061701	
	B6061702	Rapid SARS-CoV-2&Flu A&Flu B Antigen Test
	B6061703	(Colloidal Gold) / Nasal Swab
	B6061704	
BOIRON TEST & CARE	F6061701	
	F6061702	TEST 2 EN 1 COVID-19 / GRIPPE - AUTOTEST NASAL
	F6061703	2 IN 1 TEST COVID-19 / FLU NASAL SELF TEST
	F6061704	
MedRhein	M6061701	SARS-CoV-2 & FluA & FluB Antigen-Schnelltest
	M6061702	(Kolloidales Gold) / Nasenabstrich
	M6061703	Rapid SARS-CoV-2&Flu A&Flu B Antigen Test
	M6061704	(Colloidal Gold) / Nasal swab
Anbio Biotech	A6061701	
	A6061702	Rapid SARS-CoV-2 & Flu A & Flu B Antigen Test
	A6061703	(Colloidal Gold) / Nasal Swab
	A6061704	

Check it

CeCert Sp. z o.o. ul. Żurawia 32/34 00-515 Warszawa moreno voli

Kamil Szczurowski Director of *in Vitro* Diagnostic Medical Device Certification Department

www.cecert.pl e-mail: <u>biuro@cecert.pl</u> Annex 1 to the Certificate no: CeCert/073/W/E.2



DECLARATION OF CONFORMITY

Statement:

According Directive 98/79/EC on In Vitro Diagnostic Medical Devices, Annex III. This declaration of conformity is issued under the sole responsibility of Suny (Xiamen) Biotechnology Co., Ltd.

Manufacturer Information:

Manufacturer Name: Suny (Xiamen) Biotechnology Co., Ltd.

Postal Address: Building 24, No. 71, Houxiang Road, Haicang District

Postcode: 361026

City & Country: Xiamen, Fujian, China.
Telephone Number: +86 0592-6312399

Web-site: www.sunybio.cn

European Representative:

ECRP Name: Lotus NL B.V

Postal Address: Koningin Julianaplein 10,4c Verd. 2595AA, The Hague, Netherlands.

Postcode: 2595AA

City & Country: Netherlands.
Telephone Number: +31 64 41 68 999

E-Mail Address: pcfcr@lotusnl.com

In Vitro Diagnostic Directive:

Product Name: Rapid SARS-CoV-2&FluA/B Antigen Test (Colloidat Gold)

Model: \$6061701, \$6061702, \$6061703, \$6061704, \$6061705

Packing Specification: 1 Test/ Kit, 5 Tests/ Kit, 10 Tests/ Kit, 20 Test/ Kit, Other specifications

GMDN Code: 65454

Category: For Self-Test

Conformity assessment route: Declaration of Conformity 98:79:EC Annex III section 6

Statement of Responsibility:

We, Suny (Xiamen) Biotechnology Co., Ltd. here with declare with sole responsibility that our product/s mentioned above meet/s the provisions of the Directive 98/79/EC of the European Parliament and of the Council on *In Vitro Diagnostic Medical Devices*. We agree to develop, implement and maintain a documented post-production monitoring

Supplementary Information (If Applicable):

We hereby declare that the product described above, to which this declaration of conformity refers to, is in conformity with the essential requirements of the following international standards:

EN ISO 13485;2016; EN ISO 18113-1;2011; EN 13612;2002; EN ISO 15223-1;2016;

EN ISO 14971:2019; EN ISO 1813-2:2011; EN 13641:2002; EN ISO 23640:2015; EN 62366-1:2015; EN ISO 8813-2:2011; EN 13532:2002;

60 4 3 AGE

Signature and Stamp:

General Manager

For and on Behalf of M/s. Suny (Xiamen) Biotechnology Co., Ltd.

Place: Xiamen, China Date: 2022.04.15



To whom it may concern,

We, Suny (Xiamen) Biotechnology Co.,Ltd,as the manufacturer of Rapid SARS-CoV-2&Flu A&Flu B Antigen Test (Colloidal Gold), here by declare that our test is effective for, but not limited to,the mutant strain and the following variants;SARS-CoV-2 of Alpha (B1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), Epsilon (B.1.427/B.1.429), Zeta (P.2), Eta (B.1.525), Theta (P.3), Iota (B.1.526), Kappa (B.1.617.1), Lambda (C.37), Mu(B.1.621), Delta plus (AY.4.2), Omicron(B.1.1.529), Omicron(BA.5), Omicron(BQ.1),Omicron(BQ.1.1).

The aforementioned variants have several mutations in the spike protein and minimal mutations in the nucleocapsid protein.

There is no obvious difference when testing with different recombinant nucleocapsid protein antigens (Alpha, Beta, Gamma, Delta, Epsilon, Zeta, Eta, Theta, Iota, Kappa, Lambda, Mu and Delta plus), based on these different variants of SARS-CoV-2.

The theoretical analysis of the mutations in the nucleocapsid protein suggests no apparent interference for the Rapid SARS-CoV-2&Flu A&Flu B Antigen Test (Colloidal Gold) with detecting the Omicron variant of COVID-19(Includes Omicron BA.1, Omicron BA.2 Omicron BA.5, Omicron BQ.1, Omicron BQ.1.1and all related variants). We anticipate our test will be able to detect these variants.

Sincerely

Suny (Xiamen) Biotechnology Co.,Ltd.